Game over as AstraZeneca rejects final $119bn Pfizer bid
This article was originally published in Scrip
AstraZeneca has rejected a final takeover bid of $119bn from Pfizer, marking an end to a month of fevered speculation about the potential merger of the two big pharma groups. "We have rejected Pfizer's final proposal because it is inadequate and would present significant risks for shareholders, while also having serious consequences for the Company, our employees and the life-sciences sector in the UK, Sweden and the US," said AstraZeneca.
You may also be interested in...
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.